Pre-Market Activity Shows Heavy Volume And Movement For IsoRay (ISR)

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Trade-Ideas LLC identified IsoRay ( ISR) as a pre-market mover with heavy volume candidate. In addition to specific proprietary factors, Trade-Ideas identified IsoRay as such a stock due to the following factors:

  • ISR has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $23.3 million.
  • ISR traded 841,124 shares today in the pre-market hours as of 8:07 AM, representing 13.9% of its average daily volume.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in ISR with the Ticky from Trade-Ideas. See the FREE profile for ISR NOW at Trade-Ideas

More details on ISR:

IsoRay, Inc develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. Currently there is 1 analyst that rates IsoRay a buy, no analysts rate it a sell, and none rate it a hold.

The average volume for IsoRay has been 799,500 shares per day over the past 30 days. IsoRay has a market cap of $82.9 million and is part of the health care sector and health services industry. The stock has a beta of -4.34 and a short float of 7.5% with 0.49 days to cover. Shares are up 3.4% year-to-date as of the close of trading on Tuesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com Analysis:

TheStreet Quant Ratings rates IsoRay as a sell. The company's weaknesses can be seen in multiple areas, such as its poor profit margins and generally disappointing historical performance in the stock itself.

Highlights from the ratings report include:
  • The gross profit margin for ISORAY INC is currently extremely low, coming in at 10.98%. It has decreased from the same quarter the previous year. Along with this, the net profit margin of -85.08% is significantly below that of the industry average.
  • ISR's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 36.59%, which is also worse than the performance of the S&P 500 Index. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
  • The company, on the basis of net income growth from the same quarter one year ago, has significantly underperformed compared to the Biotechnology industry average, but is greater than that of the S&P 500. The net income increased by 2.1% when compared to the same quarter one year prior, going from -$0.93 million to -$0.91 million.
  • The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Biotechnology industry and the overall market, ISORAY INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • ISR, with its decline in revenue, underperformed when compared the industry average of 19.9%. Since the same quarter one year prior, revenues slightly dropped by 1.8%. Weakness in the company's revenue seems to not be hurting the bottom line, shown by stable earnings per share.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing